Monday, November 08, 2021 1:40:34 PM
November 08 2021 - 06:00AM
InvestorsHub NewsWire
Alert
Share On Facebook
San Francisco, CA -- November 8, 2021 -- InvestorsHub NewsWire -- Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceuticals, Inc. for the development of a lead cancer drug candidate.
The primary goal of the co-development project is for developing an improved formulation of the cancer drug dactinomycin. Dactinomycin, also known as actinomycin D, is an existing chemotherapy drug used to treat numerous types of cancer, including rare childhood cancers like Ewing's sarcoma and Wilms tumors. Incorporating cytotoxic drugs like dactinomycin into NanoSmart's nanoparticle delivery system can potentially provide safer toxicity profiles and improve accumulation of the drug at tumors sites compared to the free drug alone. Incorporating the drug into NanoSmart's tumor-targeting nanoparticle delivery system has the potential to result in a safer, more effective and more stable lead drug candidate.
Oncology Pharma recently licensed rights to the novel formulation. Development plans have since been established and agreed upon to advance the improved drug formulation toward eventual submission of an Investigation New Drug (IND) application to the US FDA. The plans include early formulation work, physical/chemical and in-vivo characterization of the formulation, determination of stability, pharmacokentics and toxicity. Parties The teams are currently working to implement the first phase of the development plans with the goal of establishing the feasibility of the novel dactinomycin formulation. Successful completion of this phase of the project will is intended to unlock additional pre-clinical work and enable exploration of additional formulations for future drug development.
https://www.otcmarkets.com/stock/onph/news/Oncology-Pharma-Reveals-Plans-for-Development-of-Lead-Cancer-Drug-Candidate?id=329579
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM